Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab

This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific...

ver descrição completa

Detalhes bibliográficos
Autores: Jabbour, E.J.|||0000-0003-4465-6119, Kantarjian, Hagop M.|||0000-0002-1908-3307, Goekbuget, N., Shah, B.D., Chiaretti, S., Park, J.H.|||0000-0002-2903-5130, Rijneveld, A.W., Gore, L., Fleming, S., Logan, A.C., Ribera, Jose-Maria|||0000-0003-1042-6024, Menne, T.F., Mezzi, K., Zaman, F., Velasco, K., Boissel, Nicolas|||0000-0003-2091-7927
Formato: artículo
Fecha de publicación:2024
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:310583
Acesso em linha:https://ddd.uab.cat/record/310583
https://dx.doi.org/urn:doi:10.1038/s41408-024-01179-4
Access Level:acceso abierto
Palavra-chave:Antibodies, Bispecific
Humans
Philadelphia Chromosome
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
id ES_b63e7f9818248fbdbad2bb338a20e0ba
oai_identifier_str oai:ddd.uab.cat:310583
network_acronym_str ES
network_name_str España
repository_id_str
spelling Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomabJabbour, E.J.|||0000-0003-4465-6119Kantarjian, Hagop M.|||0000-0002-1908-3307Goekbuget, N.Shah, B.D.Chiaretti, S.Park, J.H.|||0000-0002-2903-5130Rijneveld, A.W.Gore, L.Fleming, S.Logan, A.C.Ribera, Jose-Maria|||0000-0003-1042-6024Menne, T.F.Mezzi, K.Zaman, F.Velasco, K.Boissel, Nicolas|||0000-0003-2091-7927Antibodies, BispecificHumansPhiladelphia ChromosomePrecursor B-Cell Lymphoblastic Leukemia-LymphomaThis narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific T-cell-engaging immunotherapy blinatumomab in the first-line treatment setting. Current standard-of-care chemotherapeutic backbones for newly diagnosed Ph-negative BCP-ALL are based on the same overarching treatment principle: to reduce disease burden to undetectable levels and maintain lasting remission. The adult treatment landscape has progressively evolved following the adoption of pediatric-inspired regimens. However, these intense regimens are not tolerated by all, and high-risk patients still have inferior outcomes. Therefore, designing more effective and less toxic strategies remains key to further improving efficacy and safety outcomes. Overall, the treatment landscape is evolving in the frontline, and integration of blinatumomab into different standard frontline regimens may improve overall outcomes with a favorable safety profile.Universitat Autònoma de Barcelona 22024-01-0120242024-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/310583https://dx.doi.org/urn:doi:10.1038/s41408-024-01179-4reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengAgència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2021/SGR-00447open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3105832026-06-06T12:50:31Z
dc.title.none.fl_str_mv Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
title Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
spellingShingle Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
Jabbour, E.J.|||0000-0003-4465-6119
Antibodies, Bispecific
Humans
Philadelphia Chromosome
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
title_short Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
title_full Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
title_fullStr Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
title_full_unstemmed Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
title_sort Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
dc.creator.none.fl_str_mv Jabbour, E.J.|||0000-0003-4465-6119
Kantarjian, Hagop M.|||0000-0002-1908-3307
Goekbuget, N.
Shah, B.D.
Chiaretti, S.
Park, J.H.|||0000-0002-2903-5130
Rijneveld, A.W.
Gore, L.
Fleming, S.
Logan, A.C.
Ribera, Jose-Maria|||0000-0003-1042-6024
Menne, T.F.
Mezzi, K.
Zaman, F.
Velasco, K.
Boissel, Nicolas|||0000-0003-2091-7927
author Jabbour, E.J.|||0000-0003-4465-6119
author_facet Jabbour, E.J.|||0000-0003-4465-6119
Kantarjian, Hagop M.|||0000-0002-1908-3307
Goekbuget, N.
Shah, B.D.
Chiaretti, S.
Park, J.H.|||0000-0002-2903-5130
Rijneveld, A.W.
Gore, L.
Fleming, S.
Logan, A.C.
Ribera, Jose-Maria|||0000-0003-1042-6024
Menne, T.F.
Mezzi, K.
Zaman, F.
Velasco, K.
Boissel, Nicolas|||0000-0003-2091-7927
author_role author
author2 Kantarjian, Hagop M.|||0000-0002-1908-3307
Goekbuget, N.
Shah, B.D.
Chiaretti, S.
Park, J.H.|||0000-0002-2903-5130
Rijneveld, A.W.
Gore, L.
Fleming, S.
Logan, A.C.
Ribera, Jose-Maria|||0000-0003-1042-6024
Menne, T.F.
Mezzi, K.
Zaman, F.
Velasco, K.
Boissel, Nicolas|||0000-0003-2091-7927
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Antibodies, Bispecific
Humans
Philadelphia Chromosome
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
topic Antibodies, Bispecific
Humans
Philadelphia Chromosome
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
description This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific T-cell-engaging immunotherapy blinatumomab in the first-line treatment setting. Current standard-of-care chemotherapeutic backbones for newly diagnosed Ph-negative BCP-ALL are based on the same overarching treatment principle: to reduce disease burden to undetectable levels and maintain lasting remission. The adult treatment landscape has progressively evolved following the adoption of pediatric-inspired regimens. However, these intense regimens are not tolerated by all, and high-risk patients still have inferior outcomes. Therefore, designing more effective and less toxic strategies remains key to further improving efficacy and safety outcomes. Overall, the treatment landscape is evolving in the frontline, and integration of blinatumomab into different standard frontline regimens may improve overall outcomes with a favorable safety profile.
publishDate 2024
dc.date.none.fl_str_mv 2
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/310583
https://dx.doi.org/urn:doi:10.1038/s41408-024-01179-4
url https://ddd.uab.cat/record/310583
https://dx.doi.org/urn:doi:10.1038/s41408-024-01179-4
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2021/SGR-00447
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417430430777344
score 15,812455

Registos relacionados